Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

NCT07011654 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Triple-Negative Breast Cancer

Interventions

DRUG: Sacituzumab govitecan
DRUG: Naxitamab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]